Mast cells and vascular diseases

Simon Kennedy; Junxi Wu; Roger M. Wadsworth; Catherine E. Lawrence; Pasquale Maffia

doi:10.1016/j.pharmthera.2013.01.001

Mast cells and vascular diseases

Simon Kennedy^*
, Junxi Wu
, Roger M. Wadsworth
, Catherine E. Lawrence
, Pasquale Maffia

^*Corresponding author for this work

School of Regeneration and Repair

Research output: Contribution to journal › Literature review › peer-review

Abstract

Mast cells are increasingly being recognized as effector cells in many cardiovascular conditions. Many mast-cell-derived products such as tryptase and chymase can, through their enzymic action, have detrimental effects on blood vessel structure while mast cell-derived mediators such as cytokines and chemokines can perpetuate vascular inflammation. Mice lacking mast cells have been developed and these are providing an insight into how mast cells are involved in cardiovascular diseases and, as knowledge increase, mast cells may become a viable therapeutic target to slow progression of cardiovascular disease. (C) 2013 Elsevier Inc. All rights reserved.

Original language	English
Pages (from-to)	53-65
Number of pages	13
Journal	Pharmacology and Therapeutics
Volume	138
Issue number	1
DOIs	https://doi.org/10.1016/j.pharmthera.2013.01.001
Publication status	Published - Apr 2013

Keywords / Materials (for Non-textual outputs)

Mast cell
Atherosclerosis
Restenosis
Aneurysm
Vein graft
Vascular remodeling
ABDOMINAL AORTIC-ANEURYSM
SMOOTH-MUSCLE-CELLS
E-DEFICIENT MICE
SERINE-PROTEASE INHIBITOR
II TYPE-1 RECEPTOR
FC-EPSILON-RI
GASTROINTESTINAL HELMINTH INFECTION
PORCINE CORONARY-ARTERIES
EXPERIMENTAL VEIN GRAFTS
HYPER-IGE SYNDROME

Access to Document

10.1016/j.pharmthera.2013.01.001

Cite this

@article{fa3cf3aa36d74b6f9c60158447ee7feb,

title = "Mast cells and vascular diseases",

abstract = "Mast cells are increasingly being recognized as effector cells in many cardiovascular conditions. Many mast-cell-derived products such as tryptase and chymase can, through their enzymic action, have detrimental effects on blood vessel structure while mast cell-derived mediators such as cytokines and chemokines can perpetuate vascular inflammation. Mice lacking mast cells have been developed and these are providing an insight into how mast cells are involved in cardiovascular diseases and, as knowledge increase, mast cells may become a viable therapeutic target to slow progression of cardiovascular disease. (C) 2013 Elsevier Inc. All rights reserved.",

keywords = "Mast cell, Atherosclerosis, Restenosis, Aneurysm, Vein graft, Vascular remodeling, ABDOMINAL AORTIC-ANEURYSM, SMOOTH-MUSCLE-CELLS, E-DEFICIENT MICE, SERINE-PROTEASE INHIBITOR, II TYPE-1 RECEPTOR, FC-EPSILON-RI, GASTROINTESTINAL HELMINTH INFECTION, PORCINE CORONARY-ARTERIES, EXPERIMENTAL VEIN GRAFTS, HYPER-IGE SYNDROME",

author = "Simon Kennedy and Junxi Wu and Wadsworth, \{Roger M.\} and Lawrence, \{Catherine E.\} and Pasquale Maffia",

year = "2013",

month = apr,

doi = "10.1016/j.pharmthera.2013.01.001",

language = "English",

volume = "138",

pages = "53--65",

journal = "Pharmacology and Therapeutics",

issn = "0163-7258",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Mast cells and vascular diseases

AU - Kennedy, Simon

AU - Wu, Junxi

AU - Wadsworth, Roger M.

AU - Lawrence, Catherine E.

AU - Maffia, Pasquale

PY - 2013/4

Y1 - 2013/4

N2 - Mast cells are increasingly being recognized as effector cells in many cardiovascular conditions. Many mast-cell-derived products such as tryptase and chymase can, through their enzymic action, have detrimental effects on blood vessel structure while mast cell-derived mediators such as cytokines and chemokines can perpetuate vascular inflammation. Mice lacking mast cells have been developed and these are providing an insight into how mast cells are involved in cardiovascular diseases and, as knowledge increase, mast cells may become a viable therapeutic target to slow progression of cardiovascular disease. (C) 2013 Elsevier Inc. All rights reserved.

AB - Mast cells are increasingly being recognized as effector cells in many cardiovascular conditions. Many mast-cell-derived products such as tryptase and chymase can, through their enzymic action, have detrimental effects on blood vessel structure while mast cell-derived mediators such as cytokines and chemokines can perpetuate vascular inflammation. Mice lacking mast cells have been developed and these are providing an insight into how mast cells are involved in cardiovascular diseases and, as knowledge increase, mast cells may become a viable therapeutic target to slow progression of cardiovascular disease. (C) 2013 Elsevier Inc. All rights reserved.

KW - Mast cell

KW - Atherosclerosis

KW - Restenosis

KW - Aneurysm

KW - Vein graft

KW - Vascular remodeling

KW - ABDOMINAL AORTIC-ANEURYSM

KW - SMOOTH-MUSCLE-CELLS

KW - E-DEFICIENT MICE

KW - SERINE-PROTEASE INHIBITOR

KW - II TYPE-1 RECEPTOR

KW - FC-EPSILON-RI

KW - GASTROINTESTINAL HELMINTH INFECTION

KW - PORCINE CORONARY-ARTERIES

KW - EXPERIMENTAL VEIN GRAFTS

KW - HYPER-IGE SYNDROME

U2 - 10.1016/j.pharmthera.2013.01.001

DO - 10.1016/j.pharmthera.2013.01.001

M3 - Literature review

SN - 0163-7258

VL - 138

SP - 53

EP - 65

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

IS - 1

ER -

Mast cells and vascular diseases

Abstract

Keywords / Materials (for Non-textual outputs)

Access to Document

Fingerprint

Cite this